A cost-effective aptasensor capable of early diagnosis and monitoring of Alzheimer's disease with the rapid analysis of beta-amyloid peptide 1-40

• Published in: Sensors & diagnostics 2023-03, Vol.2 (2), p.49-417
• Main Authors: Khang, Ashley, Idegwu, Nnebuefe, Lee, Ji Hoon
• Format: Article
• Language: English
• ISSN: 2635-0998; 2635-0998
• DOI: 10.1039/d2sd00162d

A cost-effective biosensor with guanine chemiluminescence detection capable of sensing trace levels of beta-amyloid peptide 1-40 was developed for the early diagnosis and accurate monitoring of Alzheimer's disease (AD), which is the biggest cause of dementia-related memory loss, and other cognitive abilities. A specific DNA aptamer binds rapidly with beta-amyloid peptide 1-40 within 1 hour at room temperature. Free DNA aptamers remaining after the procedure to capture beta-amyloid peptide 1-40 in a sample electrostatically bind with luminescent dye within 5 min at room temperature. After the procedure, 3-methoxylphenylglyoxal hydrate in dimethyl furan and tetra- n -propylammonium hydroxide in deionized water were added to the solution to generate green chemiluminescence. Bright chemiluminescence, created by the internal chemiluminescence resonance energy transfer (inter-CRET) of the luminescent dye bound with the DNA aptamer and the high-energy intermediate formed in guanine chemiluminescence, was measured immediately for 20 s. The relative CL intensity decreased proportionally with the increase of the beta-amyloid peptide 1-40. The limit of detection (LOD) of the biosensor having a wide linear dynamic range (5-500 ng ml −1 ) was as low as 2 ng ml −1 . In addition, it was confirmed that the biosensor can quantify beta-amyloid peptide 1-40 with good accuracy, precision, recovery, and selectivity. We expect the principle and concepts confirmed here to be developed to be applied as a new method capable of early diagnosis and prognosis of human diseases with good reliability. A cost-effective biosensor with guanine chemiluminescence detection capable of sensing trace levels of beta-amyloid peptide 1-40 was developed for the early diagnosis and accurate monitoring of Alzheimer's disease (AD).